#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13532	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2139	629.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1699	1699	T	764	T	676	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	13532	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2139	629.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1433	1433	C	817	C	735	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24880	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	695.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1715	1715	A	784	A	705	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24880	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	695.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2349	2349	C	849	C,A	766,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24880	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	695.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2423	2423	A	766	A	713	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24880	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3566	695.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	2975	2975	C	781	C,T	703,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2148	folP	855	855	100.0	folP.l15.c4.ctg.1	1463	146.1	1	SNP	p	R229S	1	.	.	685	687	AGC	958	960	AGC	229;230;231	A;G;C	219;219;217	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4974	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3298	150.2	1	SNP	p	S91F	1	.	.	271	273	TTC	514	516	TTC	195;194;196	T;T;C	174;172;174	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4974	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3298	150.2	1	SNP	p	G95N	0	.	.	283	285	GGC	526	528	GGC	188;184;185	G,A;G;C	165,1;165;162	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4974	gyrA	2751	2751	99.96	gyrA.l6.c4.ctg.1	3298	150.2	1	SNP	p	D95G	1	.	.	283	285	GGC	526	528	GGC	188;184;185	G,A;G;C	165,1;165;162	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1562	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1244	124.9	1	SNP	p	G45D	0	.	.	133	135	GGC	397	399	GGC	190;191;193	G;G;C	172;169;171	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	736	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	896	81.4	0	.	n	.	0	A197.	DEL	197	197	A	507	507	A	190	A	173	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1437	1439	GTC	195;191;190	G;T;C	170;165;164	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	1	SNP	p	D86N	0	.	.	256	258	GAC	543	545	GAC	230;231;231	G;A;C	206;202;208	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	1	SNP	p	R87I	0	.	.	259	261	CGT	546	548	CGT	230;230;230	C,A;G;T	206,1;204;202	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	1	SNP	p	R87W	0	.	.	259	261	CGT	546	548	CGT	230;230;230	C,A;G;T	206,1;204;202	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	1	SNP	p	S87R	1	.	.	259	261	CGT	546	548	CGT	230;230;230	C,A;G;T	206,1;204;202	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	4836	parC	2304	2304	99.87	parC.l6.c17.ctg.1	2878	167.4	1	SNP	p	S88P	0	.	.	262	264	TCC	549	551	TCC	231;234;236	T;C;C	205;211;209	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4516	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2415	185.7	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1230	1232	TGC	213;212;214	T;G;C	194;195;196	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4516	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2415	185.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1440	1442	GGC	230;230;229	G;G;C	201;200;197	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1105	1107	GCA	231;231;229	G;C;A	209;207;207	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1108	1110	ATC	231;231;231	A,T;T;C	206,1;207;206	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1120	1122	GTG	246;246;243	G;T;G	222;219;221	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1120	1122	GTG	246;246;243	G;T;G	222;219;221	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1624	1626	ACC	215;214;215	A;C;C	190;187;189	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1678	1680	GCG	186;185;185	G;C;G,A	161;147;150,1	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1678	1680	GCG	186;185;185	G;C;G,A	161;147;150,1	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1801	1803	GGC	199;198;199	G;G;C	171;173;174	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1810	1812	GGC	203;202;204	G;G;C,T	176;176;176,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	4014	penA	1749	1749	100.0	penA.l6.c30.ctg.1	2171	183.5	1	SNP	p	P552S	1	.	.	1654	1656	TCG	1828	1830	TCG	182;184;180	T,G;C;G	117,11;137;139	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5422	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3237	167.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1672	1674	CCG	209;211;210	C;C;G	182;191;185	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2114	porA	1146	1146	99.56	porA.l6.c4.ctg.1	1707	123.2	0	.	p	.	0	M83fs	FSHIFT	247	247	A	512	512	C	166	C	148	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	E38G	NONSYN	112	114	GAA	373	375	GGA	239;241;239	G;G,A;A	213;214,1;218	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	G46S	NONSYN	136	138	GGC	397	399	AGC	241;240;241	A;G;C	217;218;219	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	V98I	NONSYN	292	294	GTC	553	555	ATC	237;237;234	A;T;C	216;214;212	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	A121V	NONSYN	361	363	GCC	622	624	GTC	211;208;207	G;T,G;C	192;183,1;186	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	R143E	NONSYN	427	429	AGA	688	690	GAA	219;223;227	G;A;A	191;196;200	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2776	porB1b	1035	1035	97.8	porB1b.l15.c4.ctg.1	1583	174.5	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	892	892	T	212	T	188	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9994	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4821	206.5	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2020	2022	AAT	267;265;264	A;A;T	230;227;226	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	992	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	924	106.2	1	SNP	p	V57M	1	.	.	169	171	ATG	549	551	ATG	207;209;209	A;T;G	188;189;189	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
